Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib (BMS-354825)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2018
At a glance
- Drugs Dasatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 22 Sep 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Nov 2019.
- 16 Dec 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2018.
- 06 Dec 2016 Results from this and other five studies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History